Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy

• Main Authors: David T. Beattie (Author), M. Teresa Pulido-Rios (Author), Fei Shen (Author), Melissa Ho (Author), Eva Situ (Author), Pam R. Tsuruda (Author), Patrick Brassil (Author), Melanie Kleinschek (Author), Sharath Hegde (Author)
• Format: Book
• Published: BMC, 2017-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background An unmet need remains for safe and effective treatments to induce and maintain remission in inflammatory bowel disease (IBD) patients. The Janus kinase (JAK) inhibitor, tofacitinib, has demonstrated robust efficacy in ulcerative colitis patients although, like other systemic immu...